Is BioMarin Pharmaceutical Inc. (BMRN) One of the Top Cheap Stocks to Buy With the Biggest Upside Potential?
Key takeaways
- (BMRN) One of the Top Cheap Stocks to Buy With the Biggest Upside Potential?
- (NASDAQ:BMRN) further reported that data from the three ongoing long-term extension clinical trials showed the effects of long-term treatment with VOXZOGO on measures beyond height, including bone health and arm span.
- (NASDAQ:BMRN) develops and commercializes therapies for serious and life-threatening medical conditions and rare diseases.
Is Bio Marin Pharmaceutical Inc. (BMRN) One of the Top Cheap Stocks to Buy With the Biggest Upside Potential? Noor Ul Ain Rehman Thu, May 7, 2026 at 11:41 PM GMT+7 2 min read BMRN Bio Marin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the top cheap stocks to buy with the biggest upside potential. Bio Marin Pharmaceutical Inc. (NASDAQ:BMRN) announced on May 2 new research from studies of VOXZOGO® in children with achondroplasia exhibiting positive impacts on important health indicators, including arm span and bone density. The company will present the data, along with new data from studies of VOXZOGO in hypochondroplasia, at the Pediatric Endocrine Society’s 2026 Annual Meeting (PES) in San Francisco.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) further reported that data from the three ongoing long-term extension clinical trials showed the effects of long-term treatment with VOXZOGO on measures beyond height, including bone health and arm span. According to researchers, arm span Z-scores improved from baseline in all age groups, and the arm span-to-height ratio also remained stable over time, highlighting that treatment resulted in proportional skeletal growth.
In addition, management reported that children who initiated treatment with VOXZOGO after age 5 also attained a mean difference in standing height of 10.60 cm after six years of treatment and 13.59 cm after eight years of treatment, compared with untreated natural history cohorts.